Filing Details

Accession Number:
0001192482-15-000020
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-02-05 16:58:01
Reporting Period:
2015-02-04
Filing Date:
2015-02-05
Accepted Time:
2015-02-05 16:58:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609351 Spark Therapeutics Inc. ONCE Biological Products, (No Disgnostic Substances) (2836) 462654405
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1632060 Foundation Philadelphia Of Hospital Children's 3737 Market Street
Suite 1300
Philadelphia PA 19104
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-02-04 1,000,000 $0.00 5,943,629 No 4 C Direct
Common Stock Acquisiton 2015-02-04 2,795,031 $0.00 8,738,660 No 4 C Direct
Common Stock Acquisiton 2015-02-04 61,552 $0.00 8,800,212 No 4 C Direct
Common Stock Acquisiton 2015-02-04 100,000 $23.00 8,900,212 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2015-02-04 1,000,000 $0.00 1,000,000 $0.00
Common Stock Series B Preferred Stock Disposition 2015-02-04 2,795,031 $0.00 2,795,031 $0.00
Common Stock Accrued Preferred Stock Dividends Disposition 2015-02-04 61,552 $0.00 61,552 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. Shares of Series A Preferred Stock automatically converted into shares of the Common Stock on a one-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering on February 4, 2015.
  2. Shares of Series B Preferred Stock automatically converted into shares of the Common Stock on a one-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering on February 4, 2015.
  3. Paid-in-kind dividends declared and paid on the Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock on a one-for-one basis without payment of further consideration upon the closing of the issuer's initial public offering on February 4, 2015.